Article (Scientific journals)
Upadacitinib Was Efficacious and Well-tolerated Over 30 Months in Patients With Crohn's Disease in the CELEST Extension Study.
D'Haens, Geert; Panés, Julian; Louis, Edouard et al.
2022In Clinical Gastroenterology and Hepatology, 20 (10), p. 2337-2346.e3
Peer Reviewed verified by ORBi


Full Text
Upadacinitib was efficacious and patients with IBD in the CELEST extension study_Clin Gastr_PPE.pdf
Publisher postprint (1.8 MB) Creative Commons License - Attribution, Non-Commercial, No Derivative

All documents in ORBi are protected by a user license.

Send to


Keywords :
Heterocyclic Compounds, 3-Ring; 4RA0KN46E0 (upadacitinib); EC (Creatine Kinase); Creatine Kinase/therapeutic use; Crohn Disease/drug therapy; Double-Blind Method; Heterocyclic Compounds, 3-Ring/adverse effects; Humans; Treatment Outcome; ABT-494; CDAI; IBD; JAK inhibitor
Abstract :
[en] BACKGROUND & AIMS: The long-term efficacy and safety of upadacitinib was evaluated in an open-label extension (OLE) of a phase II, double-blind, randomized trial of patients with Crohn's disease. METHODS: Patients who completed the 52-week study (CELEST) received upadacitinib in the CELEST OLE as follows: those who had received immediate-release upadacitinib 3, 6, or 12 mg twice daily or 24 mg once daily (QD) received extended-release upadacitinib 15 mg QD and those who had received immediate-release upadacitinib 12 or 24 mg twice daily as rescue therapy received extended-release upadacitinib 30 mg QD. If any patient initiating upadacitinib 15 mg QD in CELEST OLE lost response at or after week 4, the dose was escalated to upadacitinib 30 mg QD (dose-escalated group). Clinical, endoscopic, inflammatory and quality-of-life measures were assessed. RESULTS: A total of 107 CELEST study completers entered CELEST OLE. The proportion of patients with clinical remission 2.8/1.0 was maintained between week 0 and month 30 in all groups (month 30: 15 mg, 61%; 30 mg, 54%; dose-escalation, 55%). Endoscopic response was maintained in all groups (month 24: 68%, 67%, and 40%, respectively). The rates of adverse events (AEs), serious AEs, AEs leading to discontinuation, infections, serious infections, herpes zoster, and creatine phosphokinase elevation were higher with upadacitinib 30 mg vs 15 mg. CONCLUSION: Sustained long-term benefit at 30 months and further endoscopic improvements to month 24 were observed in patients with Crohn's disease receiving upadacitinib. Safety over 30 months was consistent with the known safety profile of upadacitinib. CLINICALTRIALS: gov ID no: NCT02782663.
Disciplines :
Gastroenterology & hepatology
Author, co-author :
D'Haens, Geert;  Department of Gastroenterology and Hepatology, Amsterdam University Medical
Panés, Julian;  Inflammatory Bowel Diseases Unit, Hospital Clínic Barcelona, IDIBAPS, CIBERehd,
Louis, Edouard  ;  Centre Hospitalier Universitaire de Liège - CHU > > Service de gastroentérologie, hépatologie, onco. digestive
Lacerda, Ana;  Global Pharmaceutical Research and Development, AbbVie Inc, North Chicago,
Zhou, Qian;  Data and Statistical Sciences, AbbVie Inc, North Chicago, Illinois.
Liu, John;  Pharmacovigilance and Patient Safety, AbbVie Inc, North Chicago, Ilinois.
Loftus, Edward V Jr;  Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine,
Language :
Title :
Upadacitinib Was Efficacious and Well-tolerated Over 30 Months in Patients With Crohn's Disease in the CELEST Extension Study.
Publication date :
October 2022
Journal title :
Clinical Gastroenterology and Hepatology
Publisher :
W. B. Saunders Co., Gb
Volume :
Issue :
Pages :
Peer reviewed :
Peer Reviewed verified by ORBi
Funders :
AbbVie [BE]
Commentary :
Copyright © 2022 The Authors. Published by Elsevier Inc. All rights reserved. © 2022 by the AGA Institute. Published by Elsevier Inc. This is an open access article under the CC BY license ( 1542-3565
Available on ORBi :
since 17 February 2023


Number of views
32 (1 by ULiège)
Number of downloads
264 (0 by ULiège)

Scopus citations®
Scopus citations®
without self-citations


Similar publications

Contact ORBi